Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

BACKGROUND: Marzeptacog alfa (activated) (MarzAA), a novel recombinant activated human factor VII (FVIIa) variant, was developed to provide increased procoagulant activity, subcutaneous (SC) administration, and longer duration of action in people with hemophilia. OBJECTIVES: To investigate if daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlangu, Johnny, Levy, Howard, Kosinova, Marina V., Khachatryan, Heghine, Korczowski, Bartosz, Makhaldiani, Levani, Iosava, Genadi, Lee, Martin, Del Greco, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371347/
https://www.ncbi.nlm.nih.gov/pubmed/34430790
http://dx.doi.org/10.1002/rth2.12576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371347/
https://www.ncbi.nlm.nih.gov/pubmed/34430790
http://dx.doi.org/10.1002/rth2.12576

Ejemplares similares